Provided by Tiger Fintech (Singapore) Pte. Ltd.

SITE Centers Corp.

12.74
+0.08000.63%
Post-market: 12.740.00000.00%16:23 EDT
Volume:819.30K
Turnover:10.50M
Market Cap:667.96M
PE:0.93
High:12.98
Open:12.66
Low:12.66
Close:12.66
Loading ...

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

GlobeNewswire
·
08 Nov 2024

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR Newswire
·
07 Nov 2024

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Business Wire
·
07 Nov 2024

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

GlobeNewswire
·
07 Nov 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Newsfile
·
07 Nov 2024

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Business Wire
·
07 Nov 2024

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

GlobeNewswire
·
07 Nov 2024

Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Dow Jones
·
07 Nov 2024

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

GlobeNewswire
·
07 Nov 2024

Press Release: Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow Jones
·
07 Nov 2024

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dow Jones
·
07 Nov 2024

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Business Wire
·
07 Nov 2024

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire
·
06 Nov 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

PR Newswire
·
06 Nov 2024